Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Clinical Lymphoma, Myeloma and Leukemia ; 21:S2-S3, 2021.
Article in English | EMBASE | ID: covidwho-1517533

ABSTRACT

Background: The role of upfront ASCT for NDTE MM remains under evaluation with high MRD rates following novel induction and consolidation (cons) strategies. K maintenance represents an alternative strategy to lenalidomide maintenance. The CARDAMON trial investigated K maintenance following KCd induction plus either ASCT or KCd cons. Methods: NDTE pts received 4 x KCd induction (K 20/56 mg/m2 biweekly, C 500 mg D 1,8,15, d 40mg weekly) before 1:1 randomisation to ASCT or 4 x KCd cons followed by 18 cycles K maintenance (56mg/m2 D1,8,15). Flow cytometric MRD (10-5) was assessed post induction, pre-maintenance and at 6 months maintenance. Primary endpoints were ≥VGPR post induction and 2-year PFS from randomisation. Secondary endpoints included improvements in disease response and MRD conversion following ASCT/ cons and maintenance. Results: 281 patients were registered, with 218 randomised to either ASCT or cons. The median PFS for ASCT was not yet reached vs 3.4 years for cons, with cons failing to show non-inferiority (difference in 2-year PFS 6.5%, 70% CI 1.0% to 11.1%). 196 patients received K maintenance (99 ASCT, 97 cons), 17 remain on treatment. A median of 16 cycles (1-18) were given over a median of 15.9 months (0-21.5). COVID-19 led to maintenance treatment interruptions in 41 (8 ASCT, 6 Cons) and treatment discontinuation in 15 (9 ASCT, 6 Cons). The median K dose given was 50.6mg/m2 and was similar across both arms (51.2 vs 49.4mg/m2, p=0.03). K maintenance was discontinued for PD in 14.1% (ASCT) vs 22.7% (cons), and for adverse events (AEs) in 7.1% (ASCT) vs 4.1% (cons). Most common AEs were hypertension and infections and more ≥G3 AEs were noted in ASCT vs cons (p=0.01). Patient/ clinician withdrawals from maintenance were low but occurred more in the ASCT arm (9.1% vs 1%). MRD neg patients post ASCT/ Cons had a longer PFS than MRD pos (p=0.002);with a higher MRD neg rate in the ASCT arm (53.6% vs 35.1% in Cons, p=0.01). MRD neg patients at 6 months post maintenance also had longer PFS (p=0.004 cf MRD pos patients);again with higher MRD neg rates in the ASCT arm (58.1% ASCT vs 40.5% Cons, p=0.02). There was no difference in PFS for MRD neg patients according to treatment arm from PBSCH, post-ASCT/ Cons or 6 months maintenance timepoints. Overall, 27.8% of MRD pos patients converted to MRD neg post ASCT/ Cons with more converting with ASCT (39.1% ASCT vs 16.1%, p=0.004). 23.5% of MRD pos patients converted to neg during maintenance (30.6% ASCT, 17.8%: p=0.2). Maintenance of MRD negativity over the first 6 months was similar between ASCT and Cons arms (p=0.3). There was no evidence that the timing of achievement of MRD negativity impacted PFS. Conclusions: K maintenance at 56mg/m2 weekly was deliverable and tolerable, with continued higher MRD neg rates at 6 months post-ASCT compared to post-Cons. However more ≥G3 AEs and discontinuations for AEs/ patient choice were noted for K maintenance after ASCT.

2.
International Journal of Current Research and Review ; 12(21 Special Issue):117-125, 2020.
Article in English | Scopus | ID: covidwho-1011927

ABSTRACT

Introduction: COVID-19 created a huge impact across the globe with no partiality. Majority of the cities in India is affected. India was in good shape a few months back and now, it is affected badly. There may be various causes to this situation and by seeing the current number of cases, soon India is going to take the first place in COVID-19. It is important to study various factors around the current and future state of COVID-19 in India. Aim: The objective of this research paper is to explore the current state of COVID-19 pandemic of India and the USA and understand how the COVID-19 spread is severe in India. The secondary aim of the research is to predict the confirmed cases and death rates for the forthcoming days for the USA and India as well and conclude India’s future state in COVID-19. Sample, Technique and Methods: For this research, we have used the data from 20 January 2020 to 13 October 2020 from the World Health Organization. To forecast the COVID-19 cumulative confirmed and death cases for the United States America and India, we have used FORECAST.ETS function in Microsoft Excel. The prediction calculated till 31 December 2020. Results: By 31 Oct 2020, the forecasted cumulative cases would be 8569864 in the USA and India, it would be 8288117 approximately. By 27 Nov 2020, the forecasted cumulative cases would be 9930000 in the USA and India, it would be 9941491 approximately. By 31 Dec 2020, the forecasted cumulative cases would be 11642764 in the USA and India, it would be 12023517 approximately. So, by the last week of November, India will have more COVID-19 cases than the USA and hence India will take first place globally. Conclusion: Along with the guidelines and advisory from WHO, the government of India and the department of health is taking various initiatives to control the COVID-19 spread and maintain the lower number of COVID-19 cases. However, the number of confirmed and death rates are increasing in an uncontrolled manner in the Indian sub-continent. It is not a good symptom to see that India will take over the USA’s position in COVID-19. Unless there is an initiative which can control the spread, it is not going to be easy for India by considering the population and the forthcoming winter session. © IJCRR.

3.
International Journal of Current Research and Review ; 12(16):18-28, 2020.
Article in English | Scopus | ID: covidwho-830315

ABSTRACT

Aim: The objective of this research is to explore the current state of COVID-19 pandemic at the United States of America and understand how the COVID-19 spread across various states in the county and the possible influencers to the highest number of positive cases and mortality rates. The secondary aim of the research is to predict the confirmed cases and death rates for the forthcoming days for the USA. Sample, Technique and Methods: For this research, we have used the data from 20 January 2020 to 17 July 2020. For forecasting the number of COVID-19 cases for the United States America, we have used FORECAST.ETS function in Microsoft Excel. The prediction calculated till 31 August 2020. Results: From the forecasting analysis for the United States of America, by the end of August, as on 31 August 2020, the number of cumulative confirmed cases may reach up to 6419049 (64.2 lakhs). If the situation is good, it can be controlled at 5888853(58.8 lakhs), and it may go up to 6949245(69.4 lakhs) if the scenario goes bad. By 31 August 2020, the number of cumulative death cases may go up to 166945 in the typical scenario, and however, it may reach up to 202566 if the COVID-19 situation goes wrong due to various reasons. Conclusion: There are numerous combined initiatives from the government authorities to control, treat and prevent COVID-19 at the United States of America. But still, the number of confirmed and death rates are increasing in an uncontrolled manner since it is identified in the USA. Various countries have managed the COVID-19 situation better. The USA needs to interact and learn the best practices from the nations who were able to control better. Forecasting is a powerful tool in the pandemic management which needs to be formulated strategically. © 2020, Radiance Research Academy. All rights reserved.

SELECTION OF CITATIONS
SEARCH DETAIL